TAKE growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue—−34.1%
Net Income−71.1%—
EPS (adj.)−71.1%—
Total Assets−0.7%−45.5%
Total Equity+51.1%−34.2%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

TAKE₹10.54

TAKE Limited

· Pharma & Health
₹ CrorePeersVIMTALABSSUVENMcap ₹156 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue—-34.1
Net Income-71.1—
EPS (adj.)-71.1—
Total Assets-0.7-45.5
Total Equity+51.1-34.2
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.